Verve TherapeuticsVERV
About: Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.
Employees: 255
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
36% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 25
28% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 47
4% more funds holding
Funds holding: 166 [Q2] → 172 (+6) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
3% less capital invested
Capital invested by funds: $383M [Q2] → $372M (-$10.8M) [Q3]
2.6% less ownership
Funds ownership: 93.41% [Q2] → 90.81% (-2.6%) [Q3]
65% less call options, than puts
Call options by funds: $414K | Put options by funds: $1.19M
Research analyst outlook
We haven’t received any recent analyst ratings for VERV.
Financial journalist opinion
Based on 9 articles about VERV published over the past 30 days









